高剂量伊维菌素6天疗程对比安慰剂对COVID-19门诊患者持续康复时间的影响:一项随机临床试验
ACTIV-6平台随机临床试验纳入1206例30岁以上、确诊COVID-19且急性感染症状持续≤7天的门诊患者,随机接受伊维菌素(最大目标剂量600 μg/kg,每日一次,共6天,n=602)或安慰剂(n=604)。伊维菌素组与安慰剂组持续康复时间中位数均为11天(IQR 11-12),风险比1.02(95%可信区间0.92-1.13;P=0.68),未改善持续康复时间。
要点
- 伊维菌素组与安慰剂组持续康复时间中位数均为11天(IQR 11-12),风险比1.02(95%可信区间0.92-1.13;P=0.68)。
- 第28天住院、死亡或急诊/紧急护理使用的复合终点:伊维菌素组34例(5.7%)vs 安慰剂组36例(6.0%),风险比1.0(95%可信区间0.6-1.5;P=0.53)。
- 伊维菌素组1例死亡、4例住院(0.8%);安慰剂组2例住院(0.3%)、无死亡;两组不良事件均不常见。
核心结论
- 在轻至中度COVID-19门诊患者中,与安慰剂相比,伊维菌素最大目标剂量600 μg/kg每日一次共6天未改善持续康复时间。
- 这些发现不支持在轻至中度COVID-19患者中使用伊维菌素。
研究设计与样本
- 正在进行中的加速COVID-19治疗干预和疫苗6(ACTIV-6)平台随机临床试验,旨在评估轻至中度COVID-19门诊患者的再利用疗法。
- 2022年2月16日至2022年7月22日在美国93个中心纳入1206例30岁以上、确诊COVID-19且至少2种急性感染症状持续≤7天的参与者,随访数据截至2022年11月10日。
- 参与者随机接受伊维菌素最大目标剂量600 μg/kg每日一次(n=602)或安慰剂(n=604),共6天。
主要发现
- 1206例随机接受研究药物或安慰剂的参与者中,中位(IQR)年龄48(38-58)岁,713例(59.1%)为女性,1008例(83.5%)报告至少接种2剂SARS-CoV-2疫苗。
- 持续康复(定义为至少连续3天无症状)时间中位数(IQR):伊维菌素组11(11-12)天,安慰剂组11(11-12)天;康复时间改善的风险比(获益后验概率)为1.02(95%可信区间0.92-1.13;P=0.68)。
- 第28天住院、死亡或急诊/紧急护理使用的复合终点:伊维菌素组34例(5.7%)vs 安慰剂组36例(6.0%)(风险比1.0[95%可信区间0.6-1.5];P=0.53)。
- 伊维菌素组1例死亡、4例住院(0.8%);安慰剂组2例住院(0.3%)、无死亡;两组不良事件均不常见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is unknown whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate COVID-19. OBJECTIVE: To evaluate the effectiveness of ivermectin at a maximum targeted dose of 600 μg/kg daily for 6 days, compared with placebo, for the treatment of early mild to moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: The ongoing Accelerating COVID-19 Therapeutic Interventions and Vaccines 6 (ACTIV-6) platform randomized clinical trial was designed to evaluate repurposed therapies among outpatients with mild to moderate COVID-19. A total of 1206 participants older than 30 years with confirmed COVID-19 experiencing at least 2 symptoms of acute infection for less than or equal to 7 days were enrolled at 93 sites in the US from February 16, 2022, through July 22, 2022, with follow-up data through November 10, 2022. INTERVENTIONS: Participants were randomly assigned to receive ivermectin, with a maximum targeted dose of 600 μg/kg (n = 602) daily, or placebo (n = 604) for 6 days. MAIN OUTCOMES AND MEASURES: The primary outcome was time to sustained recovery, defined as at least 3 consecutive days without symptoms. The 7 secondary outcomes included a composite of hospitalization, death, or urgent/emergent care utilization by day 28. RESULTS: Among 1206 randomized participants who received study medication or placebo, the median (IQR) age was 48 (38-58) years, 713 (59.1%) were women, and 1008 (83.5%) reported receiving at least 2 SARS-CoV-2 vaccine doses. The median (IQR) time to sustained recovery was 11 (11-12) days in the ivermectin group and 11 (11-12) days in the placebo group. The hazard ratio (posterior probability of benefit) for improvement in time to recovery was 1.02 (95% credible interval, 0.92-1.13; P = .68). Among those receiving ivermectin, 34 (5.7%) were hospitalized, died, or had urgent or emergency care visits compared with 36 (6.0%) receiving placebo (hazard ratio, 1.0 [95% credible interval, 0.6-1.5]; P = .53). In the ivermectin group, 1 participant died and 4 were hospitalized (0.8%); 2 participants (0.3%) were hospitalized in the placebo group and there were no deaths. Adverse events were uncommon in both groups. CONCLUSIONS AND RELEVANCE: Among outpatients with mild to moderate COVID-19, treatment with ivermectin, with a maximum targeted dose of 600 μg/kg daily for 6 days, compared with placebo did not improve time to sustained recovery. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04885530.
引用
- Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. JAMA. 2023. PMID: 36807465. doi:10.1001/jama.2023.1650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。